<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856284</url>
  </required_header>
  <id_info>
    <org_study_id>SYR-322_305</org_study_id>
    <secondary_id>2008-007444-34</secondary_id>
    <secondary_id>U1111-1111-7397</secondary_id>
    <secondary_id>HKCTR-862</secondary_id>
    <secondary_id>DOH-27-0709-2825</secondary_id>
    <secondary_id>09/H0703/66</secondary_id>
    <secondary_id>NMRR-09-203-3590</secondary_id>
    <nct_id>NCT00856284</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Alogliptin Plus Metformin Compared to Glipizide Plus Metformin in Patients With Type 2 Diabetes Mellitus</brief_title>
  <acronym>ENDURE</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Durability of the Efficacy and Safety of Alogliptin Compared to Glipizide When Used in Combination With Metformin in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of adding alogliptin,
      once daily (QD), compared to glipizide with metformin in diabetic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients diagnosed with type 2 diabetes mellitus, metformin is the usual first-line
      therapy in addition to diet control and exercise. For those patients with inadequate glycemic
      control with metformin monotherapy or experiencing serious side effects of metformin,
      sulfonylurea is a popular choice as a second-line oral antidiabetic treatment.

      Alogliptin is a dipeptidyl peptidase-4 inhibitor currently being developed by Takeda for use
      in patients with type 2 diabetes mellitus.

      This study is designed to further explore the durability of efficacy and safety of alogliptin
      compared to glipizide in type 2 diabetes mellitus patients whose blood sugar level is
      inadequately controlled with metformin therapy.

      The duration of this study will be approximately 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52</measure>
    <time_frame>Baseline and Week 52</time_frame>
    <description>The change from Baseline to Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104</measure>
    <time_frame>Baseline and Week 104</time_frame>
    <description>The change from Baseline to Week 104 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glycosylated Hemoglobin at Other Time Points</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 26, 39, 65, 78, and 91.</time_frame>
    <description>The change from Baseline over time in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Fasting Plasma Glucose Over Time</measure>
    <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104.</time_frame>
    <description>The change from Baseline in fasting plasma glucose (FPG) was assessed at Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104. LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline FPG and Baseline metformin dose as covariates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%</measure>
    <time_frame>Weeks 26, 52, 78, and 104.</time_frame>
    <description>The percentage of participants with HbA1c less than or equal to 6.5% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%</measure>
    <time_frame>Weeks 26, 52, 78, and 104.</time_frame>
    <description>Percentage of participants with HbA1c ≤ 7.0% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Weight Over Time</measure>
    <time_frame>Baseline and Weeks 12, 26, 39, 52, 65, 78, 91, and 104.</time_frame>
    <description>LS Means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and Baseline weight and Baseline metformin dose as covariates.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">2639</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin + Alogliptin 12.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Alogliptin 25 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin + Glipizide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alogliptin</intervention_name>
    <description>Alogliptin tablets</description>
    <arm_group_label>Metformin + Alogliptin 12.5 mg</arm_group_label>
    <arm_group_label>Metformin + Alogliptin 25 mg</arm_group_label>
    <other_name>SYR-322</other_name>
    <other_name>Nesina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin tablets</description>
    <arm_group_label>Metformin + Alogliptin 12.5 mg</arm_group_label>
    <arm_group_label>Metformin + Alogliptin 25 mg</arm_group_label>
    <arm_group_label>Metformin + Glipizide</arm_group_label>
    <other_name>Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glipizide</intervention_name>
    <description>Glipizide tablets</description>
    <arm_group_label>Metformin + Glipizide</arm_group_label>
    <other_name>Glucotrol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a diagnosis of type 2 diabetes mellitus.

          -  Must meet one of the following:

               -  Has been inadequately controlled on a stable daily dose of ≥1500 mg (or
                  documented maximum tolerated dose) of metformin for at least 2 months prior to
                  Screening.

               -  Has been inadequately controlled (as defined by a glycosylated hemoglobin 7.5 -
                  10%, inclusive) on metformin &lt;1500 mg without documented maximum tolerated dose.

          -  No treatment with antidiabetic agents other than metformin within 2 months prior to
             Screening (for Schedule A)/Pre-Screening (for Schedule B).

          -  Has body mass index within 23 kg/m^2 and 45 kg/m^2 unless the patient is Asian or of
             Asian descent, for whom the allowable body mass index will be ≥ 20 kg/m^2 and ≤ 35
             kg/m^2, inclusive.

          -  Has fasting C-peptide concentration at least 0.8 ng.

          -  If regularly using non-excluded medications, must be on a stable dose at least 4 weeks
             prior to Screening/Pre-screening.

          -  Females of childbearing potential who are sexually active must agree to use adequate
             contraception, and can neither be pregnant, lactating or intends to donate ova from
             Screening throughout the duration of the study.

          -  Must be able and willing to monitor their blood glucose concentrations with a home
             monitor, and comply with protocol requirements including scheduled clinic
             appointments.

        Exclusion Criteria:

          -  Systolic blood pressure greater than or equal to 150 mmHg and/or diastolic pressure
             greater than or equal to 90.

          -  Hemoglobin less than or equal to 12 g/dL for males and less than or equal to 10 g/dL
             for females at Screening Visit.

          -  Alanine aminotransferase greater than or equal to 2.5 times the upper limit of normal
             at Screening Visit.

          -  Serum creatinine greater than or equal to 1.5 mg/dL for males and 1.4 for females, or
             calculated creatinine clearance less than 60 L/min.

          -  Males intending to impregnate others or donate sperm before, during or within 1 month
             after participating in the study.

          -  A history of cancer other than squamous or basal cell carcinoma of the skin that has
             not been in full remission for at least 5 years.

          -  A history of laser treatment for diabetic retinopathy within 6 months of screening.

          -  Treated for diabetic gastric paresis, gastric banding, or gastric bypass.

          -  New York Heart Association Class III or IV heart failure.

          -  History of coronary angioplasty, coronary stent placement, coronary bypass surgery,
             myocardial infarction, stroke or transient ischemic attack within 3 months prior to
             screening.

          -  Known history of human immunodeficiency virus, hepatitis B or C.

          -  Alcohol or substance abuse within 2 years prior to screening.

          -  Is required to take or intends to continue taking any disallowed medication, any
             prescription medication, herbal treatment or over-the counter medication that may
             interfere with evaluation of the study medication, including:

               -  Any investigational drug within 30 days

               -  Any investigational diabetic drug within 3 months

               -  Any antidiabetic drug in the dipeptidyl peptidase-4 inhibitors or glucagon-like
                  peptide-1 mimetics classes within 90 days prior to Screening other than metformin

               -  Prior treatment with alogliptin.

               -  Weight-loss drugs

               -  Oral or systemically injected glucocorticoids

          -  A hypersensitivity allergy or anaphylactic reaction to any dipeptidyl peptidase-4
             drug, metformin or glipizide.

          -  Has a documented history or concurrent signs of significant thyroid disease (eg,
             autoimmune thyroid diseases such as Graves disease and Hashimoto thyroiditis or active
             thyroid nodules).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director, Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pell City</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sierra Vista</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Artesia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chico</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mission Viejo</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pismo Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arvada</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ridgefield</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Opa Locka</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Addison</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomington</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mishawaka</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munfordville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangor</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Peters</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Windsor</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beachwood</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Willoughby Hills</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Havertown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tipton</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hampton</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lewisburg</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasília - DF</city>
        <state>Planalto Central</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mogi das Cruzes</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fortaleza</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Collingwood</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corunna</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Etobichoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Etobicoke</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smith Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smiths Falls</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granby</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providencia</city>
        <state>Santiago</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Potsdam</city>
        <state>Brandenburg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kelkheim</city>
        <state>Hesse</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Offenbach</city>
        <state>Hesse</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>North Rhine-Westphalia</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rhineland-Palatinate</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neuwied</city>
        <state>Rhineland-Palatinate</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rhaunen</city>
        <state>Rhineland-Palatinate</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guatemala City</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wong Tai Sin</city>
        <state>Kowloon</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pok Fu Lam</city>
        <state>Southern District</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kowloon</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pécs</city>
        <state>Baranya</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <state>Borsod-Abaúj-Zemplén</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalocsa</city>
        <state>Bács-Kiskun</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <state>Békés</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Makó</city>
        <state>Csongrád</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szentes</city>
        <state>Csongrád</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nyíregyháza</city>
        <state>Szabolcs-Szatmár-Bereg</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zala</state>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Patna</city>
        <state>Bihar</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karnal</city>
        <state>Haryana</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belgaum</city>
        <state>Karnataka</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bhopal</city>
        <state>Madhya Pradesh</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trichy</city>
        <state>Tamil Nadu</state>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar-Saba</city>
        <state>Center District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <state>Central District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matan</city>
        <state>Central District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <state>Central District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hadera</city>
        <state>Haifa District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <state>Haifa District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nahariya</city>
        <state>Northern District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Safed</city>
        <state>Northern District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ashkelon</city>
        <state>Southern District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Be'er Sheva</city>
        <state>Southern District</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Holon</city>
        <state>Tel Aviv</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel- Aviv</city>
        <state>Tel Aviv</state>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zefat</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <state>Milan</state>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pistoia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <state>Honam</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <state>Hoseo</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <state>Yeongnam</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Limbazi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Talsi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tukums</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alytus</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kedainiai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palanga</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panevezys</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ipoh</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kajang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kota Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kota Bharu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Terengganu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuantan</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melaka</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taiping</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tlalnepantla</city>
        <state>Edo de Mexico</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huixquilucan Edo. de Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamilton</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otahuhu</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palmerston North</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takapuna</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiclayo</city>
        <state>Lambayeque</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lima</city>
        <state>San Juan de Miraflores</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ica</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bytom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gniewkowo</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Radom</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rzeszow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tychy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Irkutsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Elizabeth</city>
        <state>Eastern Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <state>Gauteng</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <state>Kwazulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tongaat</city>
        <state>Kwazulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amphure Muang</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiangmai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropertovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aintree-Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bath</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bournemouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stevenage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Swansea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2009</study_first_submitted>
  <study_first_submitted_qc>March 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2009</study_first_posted>
  <results_first_submitted>September 25, 2013</results_first_submitted>
  <results_first_submitted_qc>September 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2013</results_first_posted>
  <disposition_first_submitted>February 11, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>February 17, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 21, 2013</disposition_first_posted>
  <last_update_submitted>September 25, 2013</last_update_submitted>
  <last_update_submitted_qc>September 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Hyperinsulinism</keyword>
  <keyword>Hyperglycemia</keyword>
  <keyword>Glucose Intolerance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alogliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Glipizide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 310 study sites worldwide from 05 March 2009 to 17 October 2012.</recruitment_details>
      <pre_assignment_details>Participants with type 2 diabetes mellitus experiencing inadequate glycemic control while on metformin therapy were enrolled equally in 1 of 3 treatment groups: alogliptin 12.5 mg once daily (QD), alogliptin 25 mg QD, and glipizide 5 mg QD.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin + Alogliptin 12.5 mg</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Metformin + Alogliptin 25 mg</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Metformin + Glipizide</title>
          <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="880"/>
                <participants group_id="P2" count="885"/>
                <participants group_id="P3" count="874"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="873"/>
                <participants group_id="P2" count="878"/>
                <participants group_id="P3" count="869"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="472"/>
                <participants group_id="P2" count="493"/>
                <participants group_id="P3" count="427"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="408"/>
                <participants group_id="P2" count="392"/>
                <participants group_id="P3" count="447"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Hyperglycemic rescue</title>
              <participants_list>
                <participants group_id="P1" count="231"/>
                <participants group_id="P2" count="201"/>
                <participants group_id="P3" count="235"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="82"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Major protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary withdrawal</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="52"/>
                <participants group_id="P3" count="62"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator discretion</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Randomized Set included all enrolled subjects who were subsequently randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Metformin + Alogliptin 12.5 mg</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Metformin + Alogliptin 25 mg</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Metformin + Glipizide</title>
          <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="880"/>
            <count group_id="B2" value="885"/>
            <count group_id="B3" value="874"/>
            <count group_id="B4" value="2639"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="9.60"/>
                    <measurement group_id="B2" value="55.5" spread="9.81"/>
                    <measurement group_id="B3" value="55.4" spread="9.60"/>
                    <measurement group_id="B4" value="55.4" spread="9.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Categories ≥65 years and ≥75 years are not mutually exclusive. Participants ≥75 years are counted in both categories.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="734"/>
                    <measurement group_id="B2" value="710"/>
                    <measurement group_id="B3" value="723"/>
                    <measurement group_id="B4" value="2167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="146"/>
                    <measurement group_id="B2" value="175"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥75 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="461"/>
                    <measurement group_id="B2" value="433"/>
                    <measurement group_id="B3" value="433"/>
                    <measurement group_id="B4" value="1327"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="419"/>
                    <measurement group_id="B2" value="452"/>
                    <measurement group_id="B3" value="441"/>
                    <measurement group_id="B4" value="1312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="36"/>
                    <measurement group_id="B4" value="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                    <measurement group_id="B2" value="207"/>
                    <measurement group_id="B3" value="203"/>
                    <measurement group_id="B4" value="601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="66"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="557"/>
                    <measurement group_id="B2" value="555"/>
                    <measurement group_id="B3" value="533"/>
                    <measurement group_id="B4" value="1645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiracial</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="192"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="588"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="688"/>
                    <measurement group_id="B2" value="681"/>
                    <measurement group_id="B3" value="682"/>
                    <measurement group_id="B4" value="2051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI data available for 879, 885 and 872 participants in each treatment arm, respectively.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.27" spread="5.417"/>
                    <measurement group_id="B2" value="31.27" spread="5.341"/>
                    <measurement group_id="B3" value="31.11" spread="5.320"/>
                    <measurement group_id="B4" value="31.22" spread="5.358"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glycosylated hemoglobin (HbA1c)</title>
          <description>Mean HbA1c data includes 877, 883 and 870 participants in each treatment arm, respectively.</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.59" spread="0.599"/>
                    <measurement group_id="B2" value="7.61" spread="0.606"/>
                    <measurement group_id="B3" value="7.60" spread="0.617"/>
                    <measurement group_id="B4" value="7.60" spread="0.607"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HbA1c Category</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;8.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="615"/>
                    <measurement group_id="B2" value="620"/>
                    <measurement group_id="B3" value="613"/>
                    <measurement group_id="B4" value="1848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥8.0%</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="265"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="261"/>
                    <measurement group_id="B4" value="791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes duration</title>
          <description>Diabetes duration data available for 880, 884 and 874 participants in each treatment arm, respectively.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.65" spread="5.324"/>
                    <measurement group_id="B2" value="5.42" spread="4.730"/>
                    <measurement group_id="B3" value="5.48" spread="4.884"/>
                    <measurement group_id="B4" value="5.52" spread="4.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Metformin dose</title>
          <units>mg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1825.2" spread="405.59"/>
                    <measurement group_id="B2" value="1837.2" spread="373.06"/>
                    <measurement group_id="B3" value="1823.4" spread="390.63"/>
                    <measurement group_id="B4" value="1828.6" spread="389.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Glomerular filtration rate</title>
          <description>Glomerular filtration rate (GFR) was calculated using the modification of diet in renal disease (MDRD) formula and the Cockcroft-Gault formula. Data include 877, 883 and 870 participants in each treatment arm, respectively.</description>
          <units>mL/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>MDRD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.04" spread="16.586"/>
                    <measurement group_id="B2" value="82.35" spread="16.199"/>
                    <measurement group_id="B3" value="82.28" spread="16.994"/>
                    <measurement group_id="B4" value="82.56" spread="16.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cockcroft-Gault</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109.3" spread="33.40"/>
                    <measurement group_id="B2" value="109.3" spread="32.85"/>
                    <measurement group_id="B3" value="108.0" spread="32.64"/>
                    <measurement group_id="B4" value="108.9" spread="32.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="543"/>
                    <measurement group_id="B2" value="586"/>
                    <measurement group_id="B3" value="578"/>
                    <measurement group_id="B4" value="1707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Current smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="177"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="564"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52</title>
        <description>The change from Baseline to Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.</description>
        <time_frame>Baseline and Week 52</time_frame>
        <population>The Per-protocol set included all randomized patients who took at least 1 dose of double-blind study drug, with a Baseline assessment and at least 1 post-baseline assessment for that variable and who had no major protocol violations. Last observation carried forward (LOCF) was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Glipizide</title>
            <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 52</title>
          <description>The change from Baseline to Week 52 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.</description>
          <population>The Per-protocol set included all randomized patients who took at least 1 dose of double-blind study drug, with a Baseline assessment and at least 1 post-baseline assessment for that variable and who had no major protocol violations. Last observation carried forward (LOCF) was used.</population>
          <units>percentage glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.027"/>
                    <measurement group_id="O2" value="-0.76" spread="0.027"/>
                    <measurement group_id="O3" value="-0.73" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypotheses were tested in a fixed order at the 1-sided 0.0125 significance level at Weeks 52 and 104, independently: H01: Alogliptin 25 mg was inferior in HbA1c change from Baseline vs glipizide. H02: Alogliptin 12.5 mg was inferior vs glipizide. H03: Alogliptin 25 mg was not superior vs glipizide. H04: Alogliptin 12.5 mg was not superior vs glipizide. Each subsequent null hypothesis was tested only if all previously tested null hypotheses were rejected with respect to Weeks 52 and 104.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 25 mg and glipizide in HbA1c change from Baseline was less than 0.3%. If the null hypothesis H01 was rejected, then H02 was tested to show noninferiority of alogliptin 12.5 mg versus glipizide with a margin of 0.3%. Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 12.5 mg and glipizide in HbA1c change from Baseline was less than 0.3%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.059</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 25 mg and glipizide in HbA1c change from Baseline was less than 0.3%. If the null hypothesis H01 was rejected, then H02 was tested to show noninferiority of alogliptin 12.5 mg versus glipizide with a margin of 0.3%. Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 12.5 mg and glipizide in HbA1c change from Baseline was less than 0.3%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.003</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin at Other Time Points</title>
        <description>The change from Baseline over time in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 20, 26, 39, 65, 78, and 91.</time_frame>
        <population>Per-protocol set; LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Glipizide</title>
            <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin at Other Time Points</title>
          <description>The change from Baseline over time in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.</description>
          <population>Per-protocol set; LOCF was used.</population>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=341, 354, 318)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.37" spread="0.020"/>
                    <measurement group_id="O2" value="-0.40" spread="0.020"/>
                    <measurement group_id="O3" value="-0.41" spread="0.021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=370, 382, 336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.024"/>
                    <measurement group_id="O2" value="-0.60" spread="0.024"/>
                    <measurement group_id="O3" value="-0.66" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=371, 382, 336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.69" spread="0.025"/>
                    <measurement group_id="O2" value="-0.71" spread="0.025"/>
                    <measurement group_id="O3" value="-0.78" spread="0.026"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=371, 382, 336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.74" spread="0.026"/>
                    <measurement group_id="O2" value="-0.76" spread="0.025"/>
                    <measurement group_id="O3" value="-0.78" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=371, 382, 336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.026"/>
                    <measurement group_id="O2" value="-0.78" spread="0.025"/>
                    <measurement group_id="O3" value="-0.79" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=371, 382, 336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.027"/>
                    <measurement group_id="O2" value="-0.79" spread="0.026"/>
                    <measurement group_id="O3" value="-0.80" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39 (n=371, 382, 336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.026"/>
                    <measurement group_id="O2" value="-0.81" spread="0.025"/>
                    <measurement group_id="O3" value="-0.74" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 65 (n=371, 382, 336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.81" spread="0.029"/>
                    <measurement group_id="O2" value="-0.83" spread="0.028"/>
                    <measurement group_id="O3" value="-0.76" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=371, 382, 336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.030"/>
                    <measurement group_id="O2" value="-0.80" spread="0.030"/>
                    <measurement group_id="O3" value="-0.73" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 91 (n=371, 382, 336)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.76" spread="0.033"/>
                    <measurement group_id="O2" value="-0.77" spread="0.033"/>
                    <measurement group_id="O3" value="-0.68" spread="0.035"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Fasting Plasma Glucose Over Time</title>
        <description>The change from Baseline in fasting plasma glucose (FPG) was assessed at Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104. LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline FPG and Baseline metformin dose as covariates.</description>
        <time_frame>Baseline and Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104.</time_frame>
        <population>Full analysis set, which included all randomized patients who received at least 1 dose of double-blind study drug who had a Baseline assessment and at least 1 post-baseline assessment for FPG. LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Glipizide</title>
            <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Fasting Plasma Glucose Over Time</title>
          <description>The change from Baseline in fasting plasma glucose (FPG) was assessed at Weeks 2, 4, 8, 12, 16, 20, 26, 39, 52, 65, 78, 91, and 104. LS means are from an ANCOVA model with treatment, study schedule, and geographic region as class variables, and Baseline FPG and Baseline metformin dose as covariates.</description>
          <population>Full analysis set, which included all randomized patients who received at least 1 dose of double-blind study drug who had a Baseline assessment and at least 1 post-baseline assessment for FPG. LOCF was used.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="867"/>
                <count group_id="O2" value="867"/>
                <count group_id="O3" value="859"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=781, 803, 777)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="0.89"/>
                    <measurement group_id="O2" value="-11.4" spread="0.87"/>
                    <measurement group_id="O3" value="-7.7" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=863, 865, 855)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" spread="0.85"/>
                    <measurement group_id="O2" value="-11.6" spread="0.85"/>
                    <measurement group_id="O3" value="-10.2" spread="0.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="0.91"/>
                    <measurement group_id="O2" value="-11.6" spread="0.91"/>
                    <measurement group_id="O3" value="-9.3" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="0.94"/>
                    <measurement group_id="O2" value="-11.2" spread="0.94"/>
                    <measurement group_id="O3" value="-9.4" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="0.98"/>
                    <measurement group_id="O2" value="-9.9" spread="0.98"/>
                    <measurement group_id="O3" value="-7.1" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.6" spread="1.02"/>
                    <measurement group_id="O2" value="-10.1" spread="1.02"/>
                    <measurement group_id="O3" value="-5.5" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="1.06"/>
                    <measurement group_id="O2" value="-10.1" spread="1.06"/>
                    <measurement group_id="O3" value="-4.3" spread="1.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.9" spread="1.14"/>
                    <measurement group_id="O2" value="-8.4" spread="1.14"/>
                    <measurement group_id="O3" value="-0.6" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="1.22"/>
                    <measurement group_id="O2" value="-7.0" spread="1.22"/>
                    <measurement group_id="O3" value="0.9" spread="1.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 65 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="1.21"/>
                    <measurement group_id="O2" value="-5.9" spread="1.21"/>
                    <measurement group_id="O3" value="1.4" spread="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="1.47"/>
                    <measurement group_id="O2" value="-5.1" spread="1.47"/>
                    <measurement group_id="O3" value="5.1" spread="1.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 91 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.27"/>
                    <measurement group_id="O2" value="-3.4" spread="1.27"/>
                    <measurement group_id="O3" value="4.9" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104 (n=867, 867, 859)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.28"/>
                    <measurement group_id="O2" value="-3.2" spread="1.28"/>
                    <measurement group_id="O3" value="5.4" spread="1.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%</title>
        <description>The percentage of participants with HbA1c less than or equal to 6.5% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.</description>
        <time_frame>Weeks 26, 52, 78, and 104.</time_frame>
        <population>Full analysis set. Participants who did not complete the scheduled Week 26, Week 52, Week 78 or Week 104 visit were assessed based on their response at the time of discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Glipizide</title>
            <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 6.5%</title>
          <description>The percentage of participants with HbA1c less than or equal to 6.5% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.</description>
          <population>Full analysis set. Participants who did not complete the scheduled Week 26, Week 52, Week 78 or Week 104 visit were assessed based on their response at the time of discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="873"/>
                <count group_id="O2" value="878"/>
                <count group_id="O3" value="869"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.6"/>
                    <measurement group_id="O2" value="26.2"/>
                    <measurement group_id="O3" value="24.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.5"/>
                    <measurement group_id="O2" value="24.8"/>
                    <measurement group_id="O3" value="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="26.4"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5"/>
                    <measurement group_id="O2" value="24.1"/>
                    <measurement group_id="O3" value="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%</title>
        <description>Percentage of participants with HbA1c ≤ 7.0% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.</description>
        <time_frame>Weeks 26, 52, 78, and 104.</time_frame>
        <population>Full analysis set. Participants who did not complete the scheduled Week 26, Week 52, Week 78 or Week 104 visit were assessed based on their response at the time of discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Glipizide</title>
            <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Glycosylated Hemoglobin Less Than or Equal to 7.0%</title>
          <description>Percentage of participants with HbA1c ≤ 7.0% at Weeks 26, 52, 78, and 104. Participants who did not complete the scheduled Week 104 visit were assessed based on their response at the time of discontinuation.</description>
          <population>Full analysis set. Participants who did not complete the scheduled Week 26, Week 52, Week 78 or Week 104 visit were assessed based on their response at the time of discontinuation.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="873"/>
                <count group_id="O2" value="878"/>
                <count group_id="O3" value="869"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4"/>
                    <measurement group_id="O2" value="59.2"/>
                    <measurement group_id="O3" value="56.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.7"/>
                    <measurement group_id="O2" value="55.5"/>
                    <measurement group_id="O3" value="47.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.8"/>
                    <measurement group_id="O2" value="52.4"/>
                    <measurement group_id="O3" value="46.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6"/>
                    <measurement group_id="O2" value="48.5"/>
                    <measurement group_id="O3" value="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Body Weight Over Time</title>
        <description>LS Means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and Baseline weight and Baseline metformin dose as covariates.</description>
        <time_frame>Baseline and Weeks 12, 26, 39, 52, 65, 78, 91, and 104.</time_frame>
        <population>Full analysis set, LOCF was used.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Glipizide</title>
            <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Body Weight Over Time</title>
          <description>LS Means are from an ANCOVA model with treatment, study schedule and geographic region as class variables, and Baseline weight and Baseline metformin dose as covariates.</description>
          <population>Full analysis set, LOCF was used.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="867"/>
                <count group_id="O2" value="868"/>
                <count group_id="O3" value="861"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.51" spread="0.076"/>
                    <measurement group_id="O2" value="-0.53" spread="0.076"/>
                    <measurement group_id="O3" value="0.71" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="0.101"/>
                    <measurement group_id="O2" value="-0.71" spread="0.101"/>
                    <measurement group_id="O3" value="0.86" spread="0.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.109"/>
                    <measurement group_id="O2" value="-0.86" spread="0.109"/>
                    <measurement group_id="O3" value="0.97" spread="0.110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.117"/>
                    <measurement group_id="O2" value="-0.90" spread="0.117"/>
                    <measurement group_id="O3" value="0.89" spread="0.117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.70" spread="0.122"/>
                    <measurement group_id="O2" value="-0.92" spread="0.122"/>
                    <measurement group_id="O3" value="0.87" spread="0.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.78" spread="0.124"/>
                    <measurement group_id="O2" value="-0.94" spread="0.124"/>
                    <measurement group_id="O3" value="0.88" spread="0.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 91</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" spread="0.127"/>
                    <measurement group_id="O2" value="-0.88" spread="0.127"/>
                    <measurement group_id="O3" value="0.89" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.127"/>
                    <measurement group_id="O2" value="-0.89" spread="0.127"/>
                    <measurement group_id="O3" value="0.95" spread="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104</title>
        <description>The change from Baseline to Week 104 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.</description>
        <time_frame>Baseline and Week 104</time_frame>
        <population>The Per-protocol set included all randomized patients who took at least 1 dose of double-blind study drug, with a Baseline assessment and at least 1 post-baseline assessment for that variable and who had no major protocol violations. Last observation carried forward was used (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin + Alogliptin 12.5 mg</title>
            <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Metformin + Alogliptin 25 mg</title>
            <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Metformin + Glipizide</title>
            <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 104</title>
          <description>The change from Baseline to Week 104 in HbA1c (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound). The least squares (LS) means are from an analysis of covariance (ANCOVA) model with treatment, study schedule, and geographic region as class variables, and Baseline metformin dose and Baseline HbA1c as covariates.</description>
          <population>The Per-protocol set included all randomized patients who took at least 1 dose of double-blind study drug, with a Baseline assessment and at least 1 post-baseline assessment for that variable and who had no major protocol violations. Last observation carried forward was used (LOCF).</population>
          <units>percentage glycosylated hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="371"/>
                <count group_id="O2" value="382"/>
                <count group_id="O3" value="336"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.68" spread="0.037"/>
                    <measurement group_id="O2" value="-0.72" spread="0.037"/>
                    <measurement group_id="O3" value="-0.59" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypotheses were tested in a fixed order at the 1-sided 0.0125 significance level at Weeks 52 and 104, independently: H01: Alogliptin 25 mg was inferior in HbA1c change from Baseline vs glipizide. H02: Alogliptin 12.5 mg was inferior vs glipizide. H03: Alogliptin 25 mg was not superior vs glipizide. H04: Alogliptin 12.5 mg was not superior vs glipizide. Each subsequent null hypothesis was tested only if all previously tested null hypotheses were rejected with respect to Weeks 52 and 104.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 25 mg and glipizide in HbA1c change from Baseline was less than 0.3%. If the null hypothesis H01 was rejected, then H02 was tested to show noninferiority of alogliptin 12.5 mg versus glipizide with a margin of 0.3%. Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 12.5 mg and glipizide in HbA1c change from Baseline was less than 0.3%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>-0.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 25 mg and glipizide in HbA1c change from Baseline was less than 0.3%. If the null hypothesis H01 was rejected, then H02 was tested to show noninferiority of alogliptin 12.5 mg versus glipizide with a margin of 0.3%. Non-inferiority was met if the upper limit of the 1-sided 98.75% CI for the difference between alogliptin 12.5 mg and glipizide in HbA1c change from Baseline was less than 0.3%.</non_inferiority_desc>
            <param_type>LS Mean Difference</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_upper_limit>0.035</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collection of adverse events commenced from the time the participant was first administered double-blind study medication until the end of the study and from spontaneous reporting for 30 days after the end of treatment (up to 108 weeks).</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin + Alogliptin 12.5 mg</title>
          <description>Alogliptin 12.5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Metformin + Alogliptin 25 mg</title>
          <description>Alogliptin 25 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Metformin + Glipizide</title>
          <description>Glipizide 5 mg, tablets, orally, once daily and the maximum tolerated dose of metformin (1500 mg to 3300 mg daily) for up to 104 weeks. After at least 2 weeks of treatment but prior to Week 20, participants with persistent hyperglycemia (fasting plasma glucose ≥250 mg/dL) underwent a dose titration of glipizide up to 20 mg in 5-mg increments in 4-week intervals.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="86" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Silent myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Primary hyperaldosteronism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Umbilical hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Malaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Peripheral nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Muscle haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Myalgia intercostal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Polymyositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Colon cancer stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Endometrial cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer stage IIIB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Ovarian adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Rectal cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Schizophrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cervix disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Uterovaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Granulomatous pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Arterial thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Iliac artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="688" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="687" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="668" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="84" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="90" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="76" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine renal clearance decreased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="91" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="869"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="873"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="878"/>
                <counts group_id="E3" subjects_affected="65" subjects_at_risk="869"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The Week 52 results summarized in herein differ from the Week 52 results summarized in an interim analysis, because the per protocol set (PPS) defined for the final analysis included fewer subjects than the PPS defined for the interim analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>800-778-2860</phone>
      <email>clinicaltrialregistry@tpna.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

